J A Ajani1, X Wang2, S Song3, A Suzuki3, T Taketa3, K Sudo3, R Wadhwa3, W L Hofstetter4, R Komaki5, D M Maru6, J H Lee7, M S Bhutani7, B Weston7, V Baladandayuthapani2, Y Yao3, S Honjo3, A W Scott3, H D Skinner5, R L Johnson8, D Berry2. 1. Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA. Electronic address: jajani@mdanderson.org. 2. Department of Biostatistics, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA. 3. Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA. 4. Department of Cardiac and Thoracic Surgery, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA. 5. Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA. 6. Department of Pathology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA. 7. Department of Gastroenterology, Hepatology, and Nutrition, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA. 8. Department of Genetics, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA.
Abstract
PURPOSE: Operable thoracic esophageal/gastroesophageal junction carcinoma (EC) is often treated with chemoradiation and surgery but tumor responses are unpredictable and heterogeneous. We hypothesized that aldehyde dehydrogenase-1 (ALDH-1) could be associated with response. METHODS: The labeling indices (LIs) of ALDH-1 by immunohistochemistry in untreated tumor specimens were established in EC patients who had chemoradiation and surgery. Univariate logistic regression and 3-fold cross validation were carried out for the training (67% of patients) and validation (33%) sets. Non-clinical experiments in EC cells were performed to generate complimentary data. RESULTS: Of 167 EC patients analyzed, 40 (24%) had a pathologic complete response (pathCR) and 27 (16%) had an extremely resistant (exCRTR) cancer. The median ALDH-1 LI was 0.2 (range, 0.01-0.85). There was a significant association between pathCR and low ALDH-1 LI (p ≤ 0.001; odds-ratio [OR] = 0.432). The 3-fold cross validation led to a concordance index (C-index) of 0.798 for the fitted model. There was a significant association between exCRTR and high ALDH-1 LI (p ≤ 0.001; OR = 3.782). The 3-fold cross validation led to the C-index of 0.960 for the fitted model. In several cell lines, higher ALDH-1 LIs correlated with resistant/aggressive phenotype. Cells with induced chemotherapy resistance upregulated ALDH-1 and resistance conferring genes (SOX9 and YAP1). Sorted ALDH-1+ cells were more resistant and had an aggressive phenotype in tumor spheres than ALDH-1- cells. CONCLUSIONS: Our clinical and non-clinical data demonstrate that ALDH-1 LIs are predictive of response to therapy and further research could lead to individualized therapeutic strategies and novel therapeutic targets for EC patients.
PURPOSE: Operable thoracic esophageal/gastroesophageal junction carcinoma (EC) is often treated with chemoradiation and surgery but tumor responses are unpredictable and heterogeneous. We hypothesized that aldehyde dehydrogenase-1 (ALDH-1) could be associated with response. METHODS: The labeling indices (LIs) of ALDH-1 by immunohistochemistry in untreated tumor specimens were established in EC patients who had chemoradiation and surgery. Univariate logistic regression and 3-fold cross validation were carried out for the training (67% of patients) and validation (33%) sets. Non-clinical experiments in EC cells were performed to generate complimentary data. RESULTS: Of 167 EC patients analyzed, 40 (24%) had a pathologic complete response (pathCR) and 27 (16%) had an extremely resistant (exCRTR) cancer. The median ALDH-1 LI was 0.2 (range, 0.01-0.85). There was a significant association between pathCR and low ALDH-1 LI (p ≤ 0.001; odds-ratio [OR] = 0.432). The 3-fold cross validation led to a concordance index (C-index) of 0.798 for the fitted model. There was a significant association between exCRTR and high ALDH-1 LI (p ≤ 0.001; OR = 3.782). The 3-fold cross validation led to the C-index of 0.960 for the fitted model. In several cell lines, higher ALDH-1 LIs correlated with resistant/aggressive phenotype. Cells with induced chemotherapy resistance upregulated ALDH-1 and resistance conferring genes (SOX9 and YAP1). Sorted ALDH-1+ cells were more resistant and had an aggressive phenotype in tumor spheres than ALDH-1- cells. CONCLUSIONS: Our clinical and non-clinical data demonstrate that ALDH-1 LIs are predictive of response to therapy and further research could lead to individualized therapeutic strategies and novel therapeutic targets for EC patients.
Authors: Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman Journal: CA Cancer J Clin Date: 2011-02-04 Impact factor: 508.702
Authors: Nabil P Rizk; Ennapadam Venkatraman; Manjit S Bains; Bernard Park; Raja Flores; Laura Tang; David H Ilson; Bruce D Minsky; Valerie W Rusch Journal: J Clin Oncol Date: 2007-02-10 Impact factor: 44.544
Authors: Shumei Song; Dipen M Maru; Jaffer A Ajani; Chia-Hsin Chan; Soichiro Honjo; Hui-Kuan Lin; Arlene Correa; Wayne L Hofstetter; Marta Davila; John Stroehlein; Lopa Mishra Journal: Cancer Res Date: 2013-03-27 Impact factor: 12.701
Authors: Michael P Kim; Jason B Fleming; Huamin Wang; James L Abbruzzese; Woonyoung Choi; Scott Kopetz; David J McConkey; Douglas B Evans; Gary E Gallick Journal: PLoS One Date: 2011-06-13 Impact factor: 3.240
Authors: Shumei Song; Jaffer A Ajani; Soichiro Honjo; Dipen M Maru; Qiongrong Chen; Ailing W Scott; Todd R Heallen; Lianchun Xiao; Wayne L Hofstetter; Brian Weston; Jeffrey H Lee; Roopma Wadhwa; Kazuki Sudo; John R Stroehlein; James F Martin; Mien-Chie Hung; Randy L Johnson Journal: Cancer Res Date: 2014-06-06 Impact factor: 12.701
Authors: Shumei Song; Min Xie; Ailing W Scott; Jiankang Jin; Lang Ma; Xiaochuan Dong; Heath D Skinner; Randy L Johnson; Sheng Ding; Jaffer A Ajani Journal: Mol Cancer Ther Date: 2017-11-22 Impact factor: 6.261
Authors: Shumei Song; Soichiro Honjo; Jiankang Jin; Shih-Shin Chang; Ailing W Scott; Qiongrong Chen; Neda Kalhor; Arlene M Correa; Wayne L Hofstetter; Constance T Albarracin; Tsung-Teh Wu; Randy L Johnson; Mien-Chie Hung; Jaffer A Ajani Journal: Clin Cancer Res Date: 2015-03-04 Impact factor: 12.531
Authors: J A Ajani; X Wang; S Song; A Suzuki; T Taketa; K Sudo; R Wadhwa; W L Hofstetter; R Komaki; D M Maru; J H Lee; M S Bhutani; B Weston; V Baladandayuthapani; Y Yao; S Honjo; A W Scott; H D Skinner; R L Johnson; D Berry Journal: Mol Oncol Date: 2013-10-28 Impact factor: 6.603